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Purpose: To determine the safety and efﬁ  cacy of topical nepafenac 0.1% in the treatment of 
diabetic macular edema.
Methods: A consecutive case series was performed of patients treated with nepafenac 
monotherapy twice daily for diabetic macular edema. Visual acuities (VA) at baseline and 
ﬁ  nal visit were recorded. Foveal thickness, based on optical coherence tomography, was also 
recorded.
Results: Six eyes of 5 patients were included in this study. Median initial Snellen vision was 
20/100 (range, 20/40–20/400). After a mean of 210 days (range, 182–259), median ﬁ  nal VA 
was 20/75 (range, 20/40–20/400). Four eyes gained vision and two eyes maintained vision. 
Mean pre-treatment vision was 0.78 logMAR and ﬁ  nal VA was 0.67 logMAR, for a statistically 
signiﬁ  cant improvement (p   0.05). Mean initial foveal thickness was 417 microns (range, 
286–599). After a mean of 178 days (range, 91–259), mean foveal thickness was 267 microns 
(range, 158–423), showing a statistically signiﬁ  cant improvement (p   0.05). Each eye had an 
improvement in foveal thickness.
Conclusion: The results from these 6 eyes suggest that nepafenac 0.1% may have activity 
against diabetic macular edema and warrants further investigation.
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Introduction
Multiple treatment options exist for diabetic macular edema. The safety and efﬁ  cacy 
of focal laser treatment for clinically signiﬁ  cant macular edema was established 
by the Early Treatment for Diabetic Retinopathy Study (ETDRS 1985). More 
recently, intravitreal injections have become increasingly popular among clini-
cians. Based on published reports, both triamcinolone and bevacizumab have had 
success in reducing edema and improving vision (Gillies et al 2006; Haritoglou 
et al 2006).
Each treatment available has some drawbacks. While focal laser treatment can 
reduce the odds of vision loss and improve the odds of vision gain (ETDRS 1985), 
the actual reduction in edema and improvement in vision can sometimes be less than 
desired. Also, microaneurysms at the edge of the foveal avascular zone can be dif-
ﬁ  cult to treat due to the fear of permanent scotoma. In contrast, intravitreal injections 
tend to generate a rapid reduction in edema (Gillies et al 2006; Haritoglou et al 2006). 
However, each intravitreal injection carries a risk of endophthalmitis (Gillies et al 2006; 
Haritoglou et al 2006). In addition, intravitreal steroids carry the additional risks of 
glaucoma and cataract formation (Gillies et al 2006).
For cases of mild macular edema, the risks of established treatments may 
outweigh the beneﬁ  ts. Thus, alternative treatments with better safety proﬁ  les are 
desirable. Because elevated inﬂ  ammatory markers have been found in patients with Clinical Ophthalmology 2008:2(4) 690
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diabetic retinopathy, it is likely that inﬂ  ammation aids in the 
progression of vascular disease in these patients (Ke et al 
2000; Meleth et al 2005). For this reason, nonsteroidal 
antiinﬂ  ammatory drugs (NSAIDs) may be effective against 
diabetic macular edema. Topical NSAIDs are attractive 
because they have few documented risks. In addition, the 
newer topical NSAIDs have a theoretical potential to reduce 
vascular permeability in patients with diabetic macular 
edema. Nepafenac is a prodrug that is hydrolyzed into amf-
enac by uveal tissue and retina (Ke et al 2000). Based on 
animal models, nepafenac has the capability to penetrate into 
the posterior segment (Kern et al 2007; Kapin et al 2003). 
If an NSAID can penetrate to the retina, it could possibly 
reduce vascular permeability by inhibiting the inﬂ  ammatory 
cascade. Based on this hypothesis, patients with diabetic 
macular edema were started on topical nepafenac 0.1% to 
attempt to reduce the edema and improve vision. This study 
is a review of these patients with diabetic macular edema 
treated with nepafenac (Nevanac; Alcon Labs, Fort Worth, 
TX, USA).
Methods
A consecutive case series of all patients using nepafenac 
monotherapy for diabetic macular edema was performed. 
Seven eyes of six patients were evaluated for inclusion. One 
eye was excluded due to corneal transplantation for unrelated 
Fuch’s dystrophy. Inclusion criteria included evidence 
of diabetic retinopathy (microaneurysms, intraretinal 
hemorrhages, hard exudates, cotton wool spots), macular 
edema demonstrated by optical coherence tomography 
(OCT), use of topical nepafenac, and at least six months 
follow-up. Any patient with an intravitreal injection or 
focal laser treatment within the previous six months was 
excluded. No patient had cataract surgery within five 
years of the study period. Any patient with vision loss not 
solely attributed to diabetic retinopathy was excluded from 
analysis. Demographic data as well as previous treatments 
were logged. Visual acuities at baseline and at the ﬁ  nal visit 
were recorded. Foveal thickness, based on OCT, was also 
recorded at baseline and ﬁ  nal visit. A one-tailed paired t-test 
was used to compare pre- and post-treatment foveal thickness 
and pre-and post-treatment visual acuity. All patients were 
maintained on twice a day nepafenac throughout the duration 
of the study.
Results
Charts of seven eyes of six patients who were consecutively 
started on nepafenac were evaluated for inclusion. One eye 
was excluded upon the initial chart review due to corneal 
transplantation for unrelated Fuch’s dystrophy during the 
study period. Six eyes of ﬁ  ve patients were included for 
visual and OCT analysis. Patients 1, 3, and 4 were phakic 
and patients 2 and 5 underwent cataract surgery ﬁ  ve years 
prior to the study period.
The median initial Snellen vision was 20/100 (range, 
20/40–20/400). After a mean of 210 days (range, 182–259), the 
median ﬁ  nal visual acuity was 20/75 (range, 20/40–20/400). 
Four eyes gained vision, and two eyes maintained vision. 
No eye had a decrease in visual acuity. Visual acuities were 
converted to logMAR equivalent for statistical analysis. The 
mean pre-treatment vision was 0.78 logMAR and the ﬁ  nal 
visual acuity was 0.67 logMAR. The average improvement 
was statistically signiﬁ  cant based on a one-tailed paired 
t-test (p   0.05).
The mean initial foveal thickness was 417 microns (range, 
286–599). After a mean of 178 days (range, 91–259), the 
foveal thickness was 267 microns (range, 158–423). The mean 
duration of treatment for OCT analysis was less than that of the 
visual analysis because OCT was not performed at every visit. 
Each eye had an improvement in foveal thickness; Figure 1 
shows the pre- and post-treatment OCT data for patient #3. 
The average improvement was statistically signiﬁ  cant based 
on a one-tailed paired t-test (p   0.05). The differences in 
vision and OCT are demonstrated in Table 1.
Table 1 also shows the hemoglobin A1c values for the 
patients at the beginning of treatment with nepafenac and 
at the time of the ﬁ  nal OCT readings. Patient 5 did not have 
regular HbA1c values available. None of the other patients 
had evidence of improved glycemic control during the study 
period as measured by HbA1c and patients 3 and 4 actually 
had a deterioration in their glycemic control over the study 
period. One patient developed a vitreous hemorrhage 
seven months after the study period that was not consid-
ered related to nepafenac use. No complications such as 
keratitis that can be caused by topical nonsteroidal drops 
were noted.
Discussion
The results of this pilot study suggest a beneﬁ  t of topical 
nepafenac in the treatment of diabetic macular edema. One 
limitation of the study is the absence of matched controls. 
There did not, however, appear to be a signiﬁ  cant change in 
the systemic diabetes status of the patients during the study 
period. All of the patients had a reduction in foveal thickness 
in the treated eye on OCT. This is consistent with the results 
of nepafenac treatment in a rabbit model of macular edema Clinical Ophthalmology 2008:2(4) 691
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Figure 1 A OCT image of left eye in Patient #3 at baseline. Central subﬁ  eld thickness was 517 μm and total volume was 9.02 mm3. B OCT image of left eye in Patient #3 
after 259 days of nepafenac treatment. Central subﬁ  eld thickness was 158 μm and total volume was 7.35 mm3.
Table 1 Demographics, visual acuity, foveal thickness, and hemoglobin A1c (HbA1c) results before and after nepafenac treatment
Patient Age 
sex
Eye Baseline 
vision
Final 
vision
Days to ﬁ  nal 
vision
Baseline foveal 
thickness (μm)
Final foveal 
thickness (μm)
Days to ﬁ  nal 
foveal thickness
Initial 
Hba1c%
Final 
HbA1c%
1 65 M OS 20/80 20/50 193 378 215 193 7.0 6.8
2 68 M OS 20/40 20/40 209 286 226 209 6.5 6.8
3 66 F OS 20/240 20/140 259 517 158 259 7.3 9.4
4 68 F OS 20/120 20/80 227 599 423 227 4.9 6.0
5 76 M OD 20/80 20/70 182 342 267 91
5 OS 20/400 20/400 182 380 310 91
(Kapin et al 2003). Antiinﬂ  ammatory treatment has been 
proposed in the past as a mechanism for slowing diabetic 
changes in the retina. Sustained delivery of steroids in human 
diabetic eyes using a ﬂ  uocinolone implant has been shown to 
improve diabetic retinopathy scores (Pearson and Levy 2005). 
An initial trial of oral celecoxib in humans as adjunctive 
treatment for diabetic macular edema showed reduced retinal 
leakage as measured by ﬂ  uorescein angiography (E Chew pers 
comm). Animal models of diabetic macular edema have also 
shown improvement using NSAIDs. A study using diabetic Clinical Ophthalmology 2008:2(4) 692
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rats provides some insight into the potential mechanism of 
action of nepafenac. Kern and colleagues discovered that 
daily topical treatment with nepafenac produced signiﬁ  cant 
declines in diabetes-induced biochemical alterations, includ-
ing retinal prostaglandin E2 (PGE2), cyclooxygenase-2 
(COX2), and superoxide production (Kern et al 2007). In 
addition, cellular and morphologic changes such as leu-
kostasis, retinal capillary degeneration, and endothelial cell 
apoptosis were inhibited by nepafenac. Thus, it appears that 
nepafenac has a positive effect on diabetes-induced ocular 
pathology.
While a majority of patients in the current study had 
some improvement in vision, two patients had an anatomic 
improvement without a gain in visual acuity. This may be due 
to retinal ischemia causing cellular damage unresponsive 
to edema resolution. As OCT becomes more common-
place in judging success of treatment for retinal edema, it 
will be important to predict those with the potential for visual 
improvement. A previous study described the importance of 
OCT reﬂ  ectivity of the inner retinal layers in predicting visual 
improvement along with anatomic improvement (Gibran 
et al 2007). More studies are required to determine those 
patients more likely to gain vision with resolution of macular 
edema. A subset of diabetics has relatively good vision and 
mild cystic changes on OCT. These patients may be more 
likely to maintain their vision with correction of this mild 
cystic edema. Although corneal morbidities such as keratitis 
are possible with long term use of topical nonsteroidals, no 
patient in this small series had a complication attributed to 
nepafenac treatment.
This small case series suggests a beneﬁ  t from topical 
nepafenac. Considering the safety proﬁ  le of topical nepafenac, 
a study is warranted to examine the role of nepafenac in 
preventing vision loss due to diabetic macular edema in these 
patients. A larger, controlled, and randomized trial is needed 
and is being planned.
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